- Home
- PHUN vs AVTX Comparison
PHUN vs AVTX Comparison
Compare PHUN & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PHUN | AVTX |
|---|---|---|
| Founded | 2009 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 55.9M | 248.3M |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | PHUN | AVTX |
|---|---|---|
| Price | $1.84 | $16.95 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | $7.25 | ★ $32.29 |
| AVG Volume (30 Days) | 179.2K | ★ 312.8K |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,357,000.00 | $192,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $73.07 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.77 | $3.39 |
| 52 Week High | $6.29 | $20.72 |
Technical Indicators
Market Signals| Indicator | PHUN | AVTX |
|---|---|---|
| Relative Strength Index (RSI) | 37.08 | 43.19 |
| Support Level | $1.89 | $18.58 |
| Resistance Level | $1.95 | $18.54 |
| Average True Range (ATR) | 0.10 | 1.30 |
| MACD | 0.00 | -0.26 |
| Stochastic Oscillator | 20.32 | 1.91 |
Price Performance
Historical ComparisonAbout PHUN Phunware Inc.
Phunware Inc is a software company. It is a cloud platform for mobile that provides companies with the products, solutions, and data and services necessary to engage, manage and monetize its mobile application audiences. It derives maximum revenue from United States. The company has two reportable segments: Software subscriptions and services; and Advertising. It derives maximum revenue from Software subscriptions and services.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).